Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Trial Profile

Double-Blind, Randomized, Placebo-Controlled, Multi-Centre Study to Investigate the Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease With Evidence of Mucosal Ulceration

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2017

At a glance

  • Drugs Filgotinib (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Acronyms FITZROY
  • Sponsors Galapagos NV
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 May 2017 According to a Galapagos NV media release, data fromthis study will be presented at Digestive Disease Week (DDW[1]) 2017.
    • 15 Dec 2016 Results published in the Galapagos NV Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top